Have the exact product ready
Have the brand, the strength, the device (vial, single-dose pen or KwikPen) and the quantity from your prescription. A pharmacy can carry one strength of Zepbound and be out of the next, so ask about yours specifically.
Shortage status, strengths and how to find Zepbound at a pharmacy.
To find Zepbound in stock, call pharmacies with the exact product on your prescription (your strength, and whether it's a single-dose pen, a vial or the multi-dose KwikPen) and ask whether it's in stock today and when the next delivery is due. These are separate products, so a pharmacy can have one and not another. Check whether a problem is stock or coverage, and ask your prescriber to send the prescription to the pharmacy that confirms it has yours.
As of October 14, 2026, the FDA's drug shortage database has no current shortage listing for tirzepatide sold as Zepbound. That is national manufacturer supply. A pharmacy can still be out of a particular strength on a given day.
FDA's tirzepatide listings name the brand in each package description, so this checks only Zepbound packages. See FDA's listing.
Have the brand, the strength, the device (vial, single-dose pen or KwikPen) and the quantity from your prescription. A pharmacy can carry one strength of Zepbound and be out of the next, so ask about yours specifically.
A stock problem and a coverage problem can look the same at the counter, and many plans require prior authorization for these medicines. Ask: "Is the problem that you don't have it, or that the claim was rejected?"
Ask whether your strength is in stock today, whether it is on order, and when the next delivery is due. A pharmacist may also know which strengths they can usually get.
Zepbound's single-dose vials, single-dose pens and multi-dose KwikPen are separate products, each in several strengths. Tell the pharmacy exactly which one is on your prescription, and check with your prescriber before switching devices.
Check chains, grocery-store pharmacies and independents, and say you need the FDA-approved brand product as prescribed. How to ask a pharmacy if a medication is in stock has a ready-to-read script.
Once a pharmacy confirms it has your strength, ask your prescriber's office to send the prescription there. Please don't split a dose, combine strengths or stretch a pen to bridge a gap. Call your prescriber, who decides any change to your dose or medicine.
Needle phones pharmacies for you, using AI voice agents and human callers, asks for your exact Zepbound strength and form, and reports which pharmacies said they have it. Its database covers 60,000+ US pharmacies, and pay-as-you-go searches cost $1.00 per pharmacy call (credits roll over). Start a search.
NIH RxNorm, the National Library of Medicine's standard drug vocabulary, lists Zepbound in these forms and strengths as of October 14, 2026. A listed strength isn't a promise any pharmacy stocks it, and only your prescriber can change yours.
| Form | Strengths |
|---|---|
| Auto-injector pen |
|
| Multi-dose pen (KwikPen) |
|
| Single-dose vial |
|
Single-dose products are shown as total dose and volume (for example, 2.5 mg/0.5 mL). Multi-dose pens are shown by concentration and pen volume, as RxNorm records them; your prescription and pharmacy label give the dose per injection.
Zepbound is Eli Lilly's brand of tirzepatide. MedlinePlus lists tirzepatide injection to help with weight loss in certain people with obesity or overweight and weight-related medical problems, and to treat obstructive sleep apnea in adults with obesity. RxNorm lists Zepbound as auto-injector pens, 0.5 mL single-dose vials and multi-dose pens (the KwikPen), each in several strengths. RxNorm lists tirzepatide only under the Zepbound and Mounjaro brands, so there is no generic to ask for. FDA declared the tirzepatide shortage resolved on December 19, 2024.
Tell us your exact Zepbound strength and form. We phone pharmacies near you and tell you which ones say they have it.
No. As of October 14, 2026, the FDA's drug shortage database has no current shortage listing for tirzepatide sold as Zepbound. A pharmacy can still be out of a particular strength on a given day, so ask about yours.
NIH RxNorm lists Zepbound as auto-injector pens in 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL and 15 mg/0.5 mL, multi-dose pens (KwikPen) in 4.17 mg/mL × 2.4 mL, 8.33 mg/mL × 2.4 mL, 12.5 mg/mL × 2.4 mL, 16.7 mg/mL × 2.4 mL, 20.8 mg/mL × 2.4 mL and 25 mg/mL × 2.4 mL and single-dose vials in 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL and 15 mg/0.5 mL. Your prescription names your strength and form, and only your prescriber can change them.
They contain the same medicine, tirzepatide, but they are separate products. The vial, the single-dose pen and the KwikPen each have to match your prescription, so ask your prescriber before changing from one to another.
Both are tirzepatide from Eli Lilly, but they are separate brands with different approved uses. A pharmacy can't fill a Zepbound prescription with Mounjaro or the other way around; only your prescriber can change your medicine.
Medicare's temporary GLP-1 Bridge, running July 1, 2026 through December 31, 2027, covers the Zepbound KwikPen, but not Zepbound vials or single-dose pens, for people who qualify. It has a $50 copay for a one-month supply and requires prior authorization; people with type 2 diabetes, among others, are excluded. Check Medicare.gov or call 1-800-MEDICARE.